It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

In aneurysms normally chosen for surveillance, the endovascular technique slowed growth by 70% in the small phase I trial.

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.